Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

@article{Haddock2007GemcitabineCA,
  title={Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.},
  author={Michael G. Haddock and Revathi Swaminathan and Nathan R. Foster and Mark D Hauge and James A. Martenson and John K. Camoriano and Philip J. Stella and Richard C Tenglin and Paul L. Schaefer and Dennis Moore and Steven Robert Alberts},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 18},
  pages={2567-72}
}
PURPOSE A phase II study was conducted to determine the efficacy and toxicity of radiotherapy with concomitant gemcitabine and cisplatin for patients with locally advanced pancreatic adenocarcinoma. PATIENTS AND METHODS Forty-eight patients with locally advanced pancreatic adenocarcinoma received gemcitabine (30 mg/m2) and cisplatin (10 mg/m2) twice weekly during the first 3 weeks of radiotherapy. The radiation dose to the primary tumor and regional nodes was 45 Gy in 25 fractions, and the… CONTINUE READING